Sensitivity of fecal immunochemical test and risk factors for interval colorectal cancer in a French population - 02/03/23
, Manon Pruvost-Couvreur b, c , Marie Morvan b, c, Bogdan Badic d , Josiane Brousse-Potocki e , Tiphaine Kermarrec b, c , Servane Bouzeloc b, c , Jean-Baptiste Nousbaum a, b, c , Michel Robaszkiewicz a, b, c , Noémi Reboux a, Lucille Quénéhervé a, ⁎ Highlights |
• | Interval colorectal cancers after a negative faecal immunochemical test are studied. |
• | Proximal and rectal colorectal cancers are associated with negative FIT. |
• | Sex and age are not associated with colorectal cancer after negative FIT. |
• | Decreasing the FIT positivity threshold would enable to diagnose more cancers. |
Abstract |
Background |
Colorectal cancer (CRC) screening using fecal immunochemical testing (FIT) aims to detect pre-symptomatic colorectal lesions and reduce CRC mortality.
Aims |
The objectives of this study were to determine the FIT sensitivity for diagnosis of CRC, the impact of diagnostic circumstances on treatment and survival, and risk factors for interval cancer (IC).
Methods |
This population-based study evaluated the 2016–2017 CRC screening campaign in Finistère, France. CRCs were classified according to diagnostic circumstances: screen-detected CRC (SD-CRC), CRC with delayed diagnosis, IC after negative FIT (FIT-IC), post-colonoscopy CRC, CRC in non-responders and CRC in the excluded population.
Results |
This study included 909 CRCs: 248 SD-CRCs (6% of positive FIT) and 60 FIT-ICs (0.07% of negative FIT). The FIT sensitivity for CRC was 80.5% (CI95%: 76.1–84.9) at the threshold of 30 µg hemoglobin/g feces used in France. In multivariate analysis, proximal (OR:6.73) and rectal locations (OR:7.52) were associated with being diagnosed with FIT-IC rather than SD-CRC. The FIT positivity threshold maximizing the sum of sensitivity and specificity was found to be 17 µg/g, with 14 additional CRCs diagnosed compared to the current threshold.
Conclusions |
Our study confirms the good sensitivity of FIT. A decrease of the FIT detection threshold could optimize sensitivity.
Le texte complet de cet article est disponible en PDF.Keywords : Colorectal cancer, Interval cancer, Fecal immunochemical test, Screening
Abbreviations : CRC, FIT, IC, FIT-IC, SD-CRC
Plan
Vol 47 - N° 3
Article 102093- mars 2023 Retour au numéro
Article précédent
- Development and validation of a multivariable risk factor questionnaire to detect oesophageal cancer in 2-week wait patients
- Kai Man Alexander Ho, Avi Rosenfeld, Áine Hogan, Hazel McBain, Margaret Duku, Paul BD Wolfson, Ashley Wilson, Sharon MY Cheung, Laura Hennelly, Lester Macabodbod, David G Graham, Vinay Sehgal, Amitava Banerjee, Laurence B Lovat, SPIT Study Group Collaborators, Olivia Adu-Anti, Kalliopi Alexandropoulou, Ameena Ayub, Nicky Barnes, Peter Basford, Ellen Brown, Jeffrey Butterworth, Heather Button, Ellie Clarke, Alexandra Cope, Jessica Cordle, Joana Da Rocha, John DeCaestecker, Anjan Dhar, Jason Dunn, Martin Ebon, Stacey Forsey, Tracy Foster, Edith Gallagher, Helen Graham, Fiona Gregg, Philip Hall, Sandra Jackson, Nicole Kader, Sudarshan Kadri, Sandhya Kalsi, Richard Keld, Chun Lee, Hui Yann Lee, Andy CY Li, Gideon Lipman, Inder Mainie, Julie Matthews, Cheryl Mendonca, Danielle Morris, Vinod Patel, Philip Paterson, Rosemary Phillips, Elizabeth Ratcliffe, Cait Rees, Joana Da Rocha, Radu Rusu, Heather Savill, Sharan Shetty, Leena Sinha, Bob Soin, Mamoon Solkar, Darmarajah Veeramootoo, Joanne Vere, Olivia Watchorn, Hendrik Wegstapel, Tracey White, Robert Willert, Susannah Woodrow, Sebastian Zeki
- Development and Verification of a novel cuproptosis- and immune-associated based prognostic genetic signature for pancreatic ductal adenocarcinoma
- Xiang Xu, Jia-Hua Liang, Qiong-Cong Xu, Xiao-Yu Yin
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?